A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer
- Registration Number
- NCT00596648
- Lead Sponsor
- Exelixis
- Brief Summary
In Phase 1 of this study, the purpose is to evaluate the safety, tolerability, and highest safe dose of the multiple receptor tyrosine kinase inhibitor (including VEGFR2, MET, and RET) XL184 in combination with the EGFR inhibitor erlotinib administered to adults with Non-Small-Cell Lung Cancer (NSCLC). In Phase 2 of this study, the purpose is to evaluate the objective response rate of daily oral administration of XL184 with or without erlotinib in subjects with NSCLC who have progressed after responding to treatment with erlotinib.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 92
- Histologically confirmed NSCLC and Stage 3b or 4 NSCLC (Phase 1 only), Stage 3b or 4 NSCLC (Phase 2 only)
- Documented progressive disease following a prior RECIST response to monotherapy with erlotinib OR documented progressive disease following stable disease of at least 6 months on monotherapy with erlotinib (Phase 2 only)
- Must have tolerated erlotinib at the maximal dose that will be administered in Phase 2 only (or at a higher dose) for a minimum of 6 weeks
- Measurable disease per RECIST (Phase 2 only)
- At least 18 years old
- ECOG performance status of 0 or 1
- Adequate organ and marrow function
- Sexually active subjects must agree to use medically accepted methods of contraception during the course of the study and for 3 months following discontinuation of study treatment (excluding women who are not of child bearing potential and men who have been sterilized).
- Female subjects of childbearing potential must have a negative pregnancy test at enrollment
- No other diagnosis of malignancy (unless non-melanoma skin cancer, carcinoma in situ of the cervix or malignancy diagnosed ≥ 2 years previously, and currently with no evidence of disease).
- Capable of understanding and complying with the protocol, and written informed consent
-
Received anti-cancer treatment within 4 weeks, except erlotinib, prior to first dose (Phase 1 only)
-
In Phase 2 only: the subject has received:
- Small molecule inhibitors of VEGFR2/KDR OR
- An investigational anti-cancer agent within 4 weeks of the first dose of study drug OR
- An investigational agent that targets EGF or EGFR at any time OR
- An approved agent that targets EGF or EGFR (with the exception of erlotinib and gefitinib) at any time unless approved by Exelixis OR
- Anti-cancer therapy within 4 weeks (with the exception of gefitinib and erlotinib) of the first dose of study drug OR
- Prior therapy with a c-Met inhibitor
-
Not recovered to NCI CTCAE v.3 Grade ≤1 from clinically significant adverse events due to antineoplastic agents, investigational drugs, or other medications administered prior to study enrollment
-
Symptomatic or uncontrolled brain metastases requiring current treatment, including steroids and anticonvulsants
-
History of significant hematemesis or recent history of hemoptysis
-
Presence of cavitation, central lesion, or lesion abutting a major blood vessel
-
Intercurrent illness such as hypertension or cardiac arrhythmias or recent history of significant disease such as congestive heart failure
-
Pregnant or breastfeeding
-
Active bacterial or viral infection requiring systemic treatment
-
Allergy or hypersensitivity to components of either the XL184 or erlotinib formulations
-
Incapable of understanding and complying with the protocol or unable to provide informed consent
-
History of idiopathic pulmonary fibrosis or interstitial lung disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Phase 2 Arm 2 XL184 XL184 administered as a single agent Phase 2 Arm 1 XL184 XL184 + erlotinib (dose determined from Phase 1 portion of study) Phase 1 Arm XL184 Escalating doses of XL184 + erlotinib Phase 1 Arm erlotinib Escalating doses of XL184 + erlotinib Phase 2 Arm 1 erlotinib XL184 + erlotinib (dose determined from Phase 1 portion of study)
- Primary Outcome Measures
Name Time Method In Phase 1 of the study: evaluate safety, tolerability, and maximum tolerated dose of daily oral administration of XL184 in combination with erlotinib to subjects with NSCLC Assessed at each visit In Phase 1 of the study, to evaluate pharmacodynamic effects of XL184 administration in combination with erlotinib Assessed at periodic visits In Phase 1 of the study, to characterize pharmacokinetic parameters of single agent erlotinib, and of XL184 in combination with erlotinib Assessed at periodic visits (approx. every 8 weeks) In Phase 2 of the study, to estimate the objective response rate of XL184 with or without erlotinib in adults with NSCLC who have progressed after responding to erlotinib Assessed approx. every 8 weeks In Phase 2 of the study, to assess pharmacodynamic effects of XL184 administration either alone or with erlotinib Assessed at periodic visits
- Secondary Outcome Measures
Name Time Method In Phase 1 and 2 of the study, to evaluate the long-term safety and tolerability of XL184 administered either alone or in combination with erlotinib Assessed at periodic visits In Phase 2 of the study, to assess progression-free survival, duration of response, and overall survival following treatment with XL184 either alone or in combination with erlotinib Assessed at periodic visits (approx. every 8 weeks) In Phase 2 of the study, to characterize pharmacokinetic parameters of XL184 as a single agent and XL184 in combination with erlotinib in subjects with NSCLC Assessed at periodic visits (every 8 weeks)
Trial Locations
- Locations (13)
University of Chicago Medical Center
🇺🇸Chicago, Illinois, United States
Georgetown University/Lombardi Comprehensive Cancer Center
🇺🇸Washington, District of Columbia, United States
Park Nicollet Institute
🇺🇸St. Louis Park, Minnesota, United States
Summit Medical Group
🇺🇸Berkeley Heights, New Jersey, United States
Katmai Oncology Group
🇺🇸Anchorage, Alaska, United States
Stanford University Medical Center
🇺🇸Palo Alto, California, United States
Case Western Reserve University
🇺🇸Cleveland, Ohio, United States
University of California, Davis
🇺🇸Sacramento, California, United States
Dana Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Yale University School of Medicine
🇺🇸New Haven, Connecticut, United States
MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
University of Washington/ Seattle Cancer Care Alliance
🇺🇸Seattle, Washington, United States
Swedish Cancer Institute
🇺🇸Seattle, Washington, United States